AHA STAT - An American Hospital Association Blog
Facebook Twitter LinkedIn Google+ Pinterest RSS


Reining in drug prices

By AHA STAT Staff
June 13, 2017

A Senate committee today shined the spotlight on the wave of high and unexpected increases in prescription drug costs that puts an incredible financial strain on hospitals and health systems and threaten our ability to provide high quality care each and every day.

In a statement submitted to the committee’s hearing on drug prices, the AHA recommended Congress and the administration move quickly to take a number of steps that would increase competition, transparency, access and value, while fostering innovation.

The impact of skyrocketing drug prices goes far beyond hospitals’ and health systems’ budgets. Everyone eventually feels it, including patients, insurance companies, employers, the government and taxpayers. All of us. Even those who are healthy and medication-free pay more when drug prices outpace inflation through increased premiums, co-pays, deductibles and taxes. When drug companies put profits before patients, we all pay the price.

The women and men who work in America’s hospitals and health systems recognize the value of truly innovative, life-saving medicines as much as anyone. But a drug priced beyond our reach or a patient’s reach will not save anyone’s life.

Topic: Advocacy and Public Policy
Tag: drug prices


comments powered by Disqus
 

Search

Twitter

About AHA

Membership

Member Constituency Sections

Key Relationships

News Center

Performance Improvement

Advocacy Issues

Products & Services

Publications

Research & Trends

Locations

155 N. Wacker Dr.
Chicago, Illinois 60606
312.422.3000

800 10th Street, N.W.
Two CityCenter, Suite 400
Washington, DC 20001-4956
202.638.1100

1.800.424-4301